risperidone and Muscle Rigidity

risperidone has been researched along with Muscle Rigidity in 9 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Muscle Rigidity: Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in the Positive and Negative Syndrome Scale (PANSS) Total Score for Schizophrenia

The PANSS scale is used to assess the neuropsychiatric symptoms of schizophrenia. The 30-item PANSS scale provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items),and the general psychopathology subscale (16 items), each item rated on a scale of 1 (absent) to 7 (extreme). (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)

The Change From Baseline for the CGI-S Score

The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). This scale permits a global evaluation of the patient's condition at a given time. A qualified rater administered the CGI-S. (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)]

The Change From Baseline in the PSP Score

The PSP scale is used to assess the degree of dysfunction a patient exhibits over a 7-day period within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numeric score. A score between 71 and 100 indicates a mild degree of difficulty; a score between 31 and 70 indicates a moderate degree of dysfunction, and a patient with a score of 30 or less has functioning so poor he or she requires intensive supervision. (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)

Trials

3 trials available for risperidone and Muscle Rigidity

Other Studies

6 other studies available for risperidone and Muscle Rigidity